Revvityブログ
発見から治療までのイノベーションを促進
 
     
    
            
        Latest
      
    
    Optimizing functional genomics research tools by aligning their design with the ongoing evolution of the genome.
Functional Genomic Screening 
October 30, 2025  -  3  min read
       
      Functional Genomic Screening
        Mastering screening: Validating and following up on hits from loss-of-function screens.
            February 20, 2025 -
            2 min read
          
          
         
      Small Molecule Drug Discovery
        Enhancing drug development with advanced immune profiling.
            February 19, 2025 -
            2 min read
          
          
         
      Cell and Gene Therapy
        Cell and gene therapy gets on point with base editors.
            February 19, 2025 -
            6 min read
          
          
         
      Cancer
        Lentiviral sgRNA CRISPR screening in primary human immune cells.
            February 19, 2025 -
            2 min read
          
          
         
      Reproductive Health
        Empowering lives: Revvity's commitment to rare disease awareness.
            February 19, 2025 -
            3 min read
          
          
         
       
      Cell and Gene Therapy
        Base editing goes big: A role in functional pooled screening.
            February 14, 2025 -
            4 min read
          
          
         
      Cell and Gene Therapy
        Exploring the potential of base editing for sickle cell disease.
            February 14, 2025 -
            4 min read
          
          
         
      Cell and Gene Therapy
        Revvity supports Abata Therapeutics to impact the trajectory of autoimmune disease with engineered Treg cell therapies.
            February 7, 2025 -
            1 min read
          
          
         
      Disease Research
        What to consider when selecting a centrifuge for your lab.
            January 24, 2025 -
            3 min read
          
          
         
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                  